Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of antidepressants: clinical aspects.

Acta psychiatrica Scandinavica. Supplementum - 1 Jan 1997

Bertilsson L, Dahl M L, Tybring G

Abstract excerpt

Plasma concentrations and response to antidepressants vary considerably between patients treated with similar dosages. Most antidepressants and also antipsychotics are metabolized by the polymorphic debrisoquine/sparteine hydroxylase, i.e., cytochrome P450 (CYP)2D6. About 7% of Caucasians are poor metabolizers (PM), and such patients might develop adverse drug reactions when treated with recommended doses of, for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Interactions

Share to Genetic Variation

Share to Polymorphism, Genetic

Share to Racial Groups

Source

Identifiers

PMID: 9265947
DOI: 10.1111/j.1600-0447.1997.tb05954.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of antidepressants: clinical aspects.PMID 9265947Read ↗

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implicationSemantic proximity Read ↗

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.Semantic proximity Read ↗

Pharmacogenetics and psychopharmacotherapySemantic proximity Read ↗

Pharmacogenomics and antidepressant drugs.Semantic proximity Read ↗

Pharmacogenetic studies: a tool to improve antidepressant therapy.Semantic proximity Read ↗

Pharmacogenetics-guided dose modifications of antidepressants.Semantic proximity Read ↗

Pharmacogenetics and drug metabolism of newer antidepressant agents.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

Pharmacogenetics of mood disorders: what clinicians need to know.Semantic proximity Read ↗

Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.Semantic proximity Read ↗

Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.